Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia
The availability of novel targeted agents has revolutionized the management of chronic lymphocytic leukemia (CLL). Both B-cell lymphoma 2 (BCL2) and Bruton tyrosine kinase (BTK) inhibitors are highly effective agents for CLL treatment. Several clinical trials have demonstrated the efficacy and safet...
Spremljeno u:
| Glavni autori: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Wolters Kluwer Medknow Publications
2023-10-01
|
| Serija: | Hematology/Oncology and Stem Cell Therapy |
| Teme: | |
| Online pristup: | https://journals.lww.com/10.56875/2589-0646.1039 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|